Efprezimod alfa clinical trials
Also written MK-7110 and CD24Fc.
How each study uses efprezimod alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2020 | 3 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (6) · Tianhong Li (1)
Studies
Open first, then newest update. How each study uses efprezimod alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC StudyTerminatedPhase 1/2Tianhong LiNCT04552704Written as CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24FcHow we know
- Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)CompletedPhase 2Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02663622Written as Efprezimod alfaHow we know
- Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)CompletedPhase 3Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT04317040Written as Efprezimod alfaHow we know
- Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)TerminatedPhase 3Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT04095858Written as Efprezimod alfaHow we know
- Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)TerminatedPhase 2Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT03960541Written as Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein)How we know
- Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)CompletedPhase 1Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02650895Written as Efprezimod alfaHow we know
- CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)WithdrawnPhase 1/2Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT04060407Written as CD24FcHow we know
Codes
What other systems call efprezimod alfa · ClinicalTrials.gg INT016575
- UNII (FDA) FN12T66RMNEFPREZIMOD ALFAOne source FDA
- NCI Thesaurus C125903Efprezimod AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FN12T66RMN | EFPREZIMOD ALFA | One source FDA |
| NCI Thesaurus | C125903 | Efprezimod Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.